ASCO 2023 | OpACIN-neo & PRADO 3-year results in stage III melanoma: personalized neoadjuvant IO benefits

Irene Reijers, MD / PhD student, Netherlands Cancer Institute, Amsterdam, Netherlands, shares the 3-year results of the Phase II OpACIN-neo (NCT02977052) trial and the PRADO extension cohort, which investigated neoadjuvant ipilimumab plus nivolumab in high-risk stage III melanoma. OpACIN-neo excluded adjuvant systemic therapy (ST) after therapeutic lymph node dissection (TLND), while PRADO adopted a personalized approach. In PRADO, patients with a major pathologic response (MPR; less than or equal to 10% viable tumor) omitted TLND and adjuvant ST, while patients with pathologic non-response (pNR; more than 50% viable tumor) received adjuvant ST with or without radiotherapy after TLND. The study shows that omitting TLND in MPR patients had no adverse effect on long-term survival. However, adding adjuvant ST in pNR patients improved relapse-free survival (RFS) and distant metastasis-free survival (DMFS). The findings suggest that personalized neoadjuvant immunotherapy based on the pathologic response may benefit melanoma patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.